Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells

British Journal of Ophthalmology

Volumn 91, Issue 6, 2007, Pages 827-831

  Peters, Swaantje ^a   Julien, Sylvie ^a   Heiduschka, Peter ^a   Grisanti, Salvatore ^a   Ziemssen, Focke ^a   Adler, Martin ^a   Schraermeyer, Ulrich ^a   Bartz Schmidt, Karl Ulrich ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DEXTRAN; ISOTHIOCYANIC ACID; VASCULOTROPIN;

ANIMAL CELL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASSAY; ATTENUATION; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CHOROID; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; FREEZING; NONHUMAN; PRIORITY JOURNAL; SWINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CAPILLARY PERMEABILITY; CELL PROLIFERATION; CELLS, CULTURED; CHOROID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FREEZING; SWINE;

EID: 34249777252     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.109702     Document Type: Article

References (25)

1. Marshall J. The role of bevacizumab as first-line therapy for colon cancer. Semin Oncol 2005;32(Suppl 9):S43-7.
2. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803.
3. Hicklin DJ, Ellis LM. Role of vascular endothelial growth factor pathway in tumor growth and angiogenesis. JCO 2005,23:1011-27.
4. Aiello LP, Avery RL, Arrig PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
5. Schlingenmann RO. Role of growth factors and the wound healing response in age-related macular degeneration. Graefe's Arch Clin Exp Ophthalmol 2004;242:91-101.
6. Sakamoto T, Sakamoto H, Murphy TL, et al. Vessel formation by choroidal endothelial cells in vitro is modulated by retinal pigment epithelial cells. Arch Ophthalmol 1995,113:512-20.
7. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006,113:363-72.
8. Rosenfeld PJ, Moshfeghi AA, Puliafito CA (b). Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-5.
9. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-90.
10. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
11. Hoffmann S, Spee C, Murata T, et al. Rapid isolation of choriocapillary endothelial cells by Lycopersicon esculentum-coated Dynabeads. Graefe's Arch Clin Exp Ophthalmol 1998;236:779-84.
12. Muller WA, Gimbone MA Jr. Plasmalemmal proteins of cultured vascular endothelial cells exhibit apical-basal polarity: analysis by surface-selective iodination. J Cell Biol 1986;103:2389-402.
13. Wang Y, Dei D, Vanderlaan M, et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004;7:335-45.
14. Roberts WG, Palade GE. Increased microvascular permeability and endothelial cell fenestration induced by vascular endothelial growth factor. J Cell Sci 1995;108:2369-79.
15. Uitto VJ, Bailie D, Wu Q, et al. Fusobacterium nucleatum increases collagenase 3 production and migration of epithelial cells. Infect Immun 2005,73:1171-9.
16. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
17. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005,112:1035-47.
18. Lee S, Jilani SM, Nikolova GV, et al. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005;169:681-91.
19. Robinson GS, Ju M, Shih SC, et al. Nonvascular role for VEGF: VEGFR-1,2 activity is critical for neuronal retinal development. FASEB J 2001,15:1215-7.
20. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006,355:1419-31.
21. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
22. Nguyen QD, Shah S, Tatlipinar S, et al. Bevacizumab suppresses choroidal neovascularization caused by pathological myopia. Br J Ophthalmol 2005;89:1368-70.
23. Reichel E. Intravitreal bevacizumab for choroidal neovascularization and cystoid macular edema: a cost-effective treatment? Ophthalmic Surg Lasers Imaging 2005;36:270-1.
24. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-9.
25. Lai BK, Varma S, Pappas PJ, et al. VEGF increases permeability of the endothelial cell monolayer by activation of PKB/akt, endothelial nitric-oxide synthase, and MAP kinase pathways. Microvasc Res 2001;62:252-62.